We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study.
- Authors
Millonig, A.; Rudzki, D.; Hölzl, M.; Ehling, R.; Gneiss, C.; Künz, B.; Berger, T.; Reindl, M.; Deisenhammer, F.
- Abstract
Background Neutralizing antibodies (NABs) against interferon beta (IFNβ) are associated with a loss of IFNβ bioactivity and clinical effectiveness. To date, there are no anti-NAB strategies available. The primary objective of this trial was to investigate whether intravenous IFNβ-1b can restore bioactivity in NAB-positive patients with MS. Methods NAB-positive patients with MS were treated with 8 MIU IFNβ-1b s.c., 8 MIU i.v., and 16 MIU i.v. Each application was preceded by a wash-out period of 1 week. Blood samples were collected before, 3, 12, and 24 h after each administration. Myxovirus protein A (MxA) RNA and protein levels were determined. The study has been approved by the local ethics committee. Results Five patients completed the study. NAB titers ranged from 42 to 4482 neutralizing units. Median MxA protein (1821, range 12-3234) and RNA (2186, range 114-7525) area under the curve levels for the four measurements at each IFNβ injection were significantly higher after i.v. application of 16 MIU as compared with both 8-MIU dosages, which were 743 (0-2709) for MxA protein after 8 MIU i.v. and 254 (0-1200) after s.c., and 1763 (25-7188) for MxA RNA after 8 MIU i.v., and 557 (5-2265) after s.c. applications. NAB titers decreased significantly and transiently after infusion of 16 MIU IFNβ-1b but not after both forms of 8 MIU applications. Typical side effects could be controlled by paracetamol. No allergic reaction was observed. Discussion The results indicate that i.v. administration of IFNβ can restore bioavailability of IFNβ in patients with NABs.
- Subjects
INTERFERONS; ANTIVIRAL agents; ANTINEOPLASTIC agents; MULTIPLE sclerosis; IMMUNOGLOBULINS; ORTHOMYXOVIRUSES; ACETAMINOPHEN
- Publication
Multiple Sclerosis (13524585), 2009, Vol 15, Issue 8, p977
- ISSN
1352-4585
- Publication type
Article
- DOI
10.1177/1352458509105384